Quince Therapeutics announces 1-for-10 reverse stock split effective April 10, 2026

Quince Therapeutics, Inc.

Approximately 16.3M shares outstanding post-split; ratio 1-for-10.
Certificate of Amendment filed with Delaware on April 9; effective 11:59 PM ET April 10.
Split-adjusted trading on Nasdaq begins at market open April 13; new CUSIP 22053A206.
Stock options and warrants proportionally adjusted; no change to rights or preferences.
Equiniti Trust Company appointed as exchange agent; fractional shares paid in cash.

item 3.03 item 5.03 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Equity Issuances SEC 8-K Item 3.02/3.03 confidence 0.9

Quince Therapeutics, Inc. issued common stock.

Security: common stock

Exact text from the filing

every ten (10) shares of the Company’s issued and outstanding common stock will be automatically combined and converted into one (1) issued and outstanding share of common stock

View on SEC.gov

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

Quince Therapeutics, Inc.: Filed Certificate of Amendment to effect a 1-for-10 reverse stock split of common stock, effective April 10, 2026 (effective 2026-04-10).

Change: charter amendment
Effective: 2026-04-10

Exact text from the filing

on April 9, 2026, the Company filed the Certificate of Amendment with the Secretary of State of the State of Delaware, which will be effective at 11:59 pm Eastern Time on April 10, 2026.

View on SEC.gov

32 equity issuances filed in the last 30 days. Browse all equity issuances →

Quince Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-26-149021

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.